LB Pharmaceuticals opened lower at $44.37, compared with its previous close of $44.71. In the last trading session, the stock traded between $41.88 and $44.37. It showed a downward intraday trend.
An investment of $100 made 2 years ago in LB Pharmaceuticals is now worth
$ 245.78
Giving a profit of
$ 145.78 (145.78%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
$-2.19 (-4.90%)
Day High
$44.37
Day Low
$41.88
Day Open
$44.37
Prev Close
$44.71
Volume
3,62,182
1W Return
4.14%
1M Return
18.27%
3M Return
-6.24%
6M Return
30.05%
1Y Return
166.08%
Market Cap ($ Mn)
1,376
PE Ratio
488.93
PB Ratio
4.12
PEG Ratio
-
ROE
-24.41%
ROCE
-17.64%
EPS (TTM)
-
1 Week
4.14%
1 Month
18.27%
3 Months
-6.24%
6 Months
30.05%
9 Months
76.50%
LB Pharmaceuticals files prospectus for mixed shelf offering
LB Pharmaceuticals filed a prospectus for a mixed shelf offering with the US SEC. Specific terms including amount and security type remain undisclosed. The filing allows for flexible future capital raising under shelf registration rules.
1mo agoLB Pharmaceuticals Q2 Results: EPS Misses Estimate, Losses Widen
LB Pharmaceuticals Q2 EPS of $(1.71) missed the $(0.80) estimate by 113.75%. Losses widened 87.41% YoY from $(13.58), signaling continued pressure on profitability and a significant deviation from analyst expectations.
3mo agoLB Pharma expects NOVA-2 trial results in H1 2027
LB Pharmaceuticals Inc has updated the timeline for its pivotal Phase 3 NOVA-2 clinical trial of LB-102, targeting topline results in the first half of 2027. A pre-NDA meeting with the FDA is anticipated in the second half of 2027. The randomized, double-blind, placebo-controlled trial aims to enroll approximately 460 patients across 25 sites in the U.S. to evaluate the efficacy and safety of LB-102 for schizophrenia.
3mo agoBMO Capital initiates coverage on LB Pharmaceuticals with outperform rating
BMO Capital analyst Malcolm Hoffman initiated coverage on LB Pharmaceuticals (NASDAQ: LBRX) with an outperform rating and a price target of $46.
3mo agoLB Pharmaceuticals grants inducement award to new SVP
LB Pharmaceuticals Inc granted an inducement equity award to Christopher Zergebel, its new Senior Vice President, Clinical Operations, under Nasdaq Listing Rule 5635(c)(4). The award consists of an option to purchase 75,000 shares with a ten-year term and an exercise price of $32.95 per share.
4mo agoLB Pharmaceuticals appoints Christopher Zergebel as SVP Clinical Operations
LB Pharmaceuticals Inc appointed Christopher Zergebel as Senior Vice President, Clinical Operations to oversee its late-stage clinical programs. The company is actively conducting Phase 3 and Phase 2 trials for LB-102 in schizophrenia and bipolar depression, respectively, with a Phase 2 trial for major depressive disorder planned for early next year.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in LB Pharmaceuticals is now worth
$ 245.78
Giving a profit of
$ 145.78 (145.78%)
Note: Past profits do not guarantee future returns.
